» Articles » PMID: 38864903

Azole Resistance in Veterinary Clinical Aspergillus Fumigatus Isolates in the Netherlands

Overview
Journal Mycopathologia
Date 2024 Jun 12
PMID 38864903
Authors
Affiliations
Soon will be listed here.
Abstract

Aspergillus fumigatus is a saprophytic fungal pathogen that causes opportunistic infections in animals and humans. Azole resistance has been reported globally in human A. fumigatus isolates, but the prevalence of resistance in isolates from animals is largely unknown. A retrospective resistance surveillance study was performed using a collection of clinical A. fumigatus isolates from various animal species collected between 2015 and 2020. Agar-based azole resistance screening of all isolates was followed by in vitro antifungal susceptibility testing and cyp51A gene sequencing of the azole-resistant isolates. Over the 5 year period 16 (11.3%) of 142 A. fumigatus culture-positive animals harbored an azole-resistant isolate. Resistant isolates were found in birds (15%; 2/13), cats (21%; 6/28), dogs (8%; 6/75) and free-ranging harbor porpoise (33%; 2/6). Azole-resistance was cyp51A mediated in all isolates: 81.3% (T-67G/)TR/L98H, 12.5% TR/Y121F/T289A. In one azole-resistant A. fumigatus isolate a combination of C(-70)T/F46Y/C(intron7)T/C(intron66)T/M172V/E427K single-nucleotide polymorphisms in the cyp51A gene was found. Of the animals with an azole-resistant isolate and known azole exposure status 71.4% (10/14) were azole naive. Azole resistance in A. fumigatus isolates from animals in the Netherlands is present and predominantly cyp51A TR-mediated, supporting an environmental route of resistance selection. Our data supports the need to include veterinary isolates in resistance surveillance programs. Veterinarians should consider azole resistance as a reason for therapy failure when treating aspergillosis and consider resistance testing of relevant isolates.

Citing Articles

Comprehensive Review of Environmental Surveillance for Azole-Resistant : A Practical Roadmap for Hospital Clinicians and Infection Control Teams.

Tashiro M, Nakano Y, Shirahige T, Kakiuchi S, Fujita A, Tanaka T J Fungi (Basel). 2025; 11(2).

PMID: 39997390 PMC: 11856238. DOI: 10.3390/jof11020096.


Aspergillus spp., aspergillosis and azole usage in animal species in Europe: Results from a multisectoral survey and review of recent literature.

de Jong J, Heuvelink A, Dieste Perez L, Holstege M Med Mycol. 2025; 63(2).

PMID: 39890594 PMC: 11835019. DOI: 10.1093/mmy/myaf009.


Pan-azole resistance in clinical isolates carrying TR34/L98H from birds and mammals in Belgium.

Debergh H, Haesendonck R, Botteldoorn N, Martel A, Pasmans F, Saegerman C One Health. 2024; 19:100907.

PMID: 39430230 PMC: 11490837. DOI: 10.1016/j.onehlt.2024.100907.

References
1.
Wiederhold N, Verweij P . Aspergillus fumigatus and pan-azole resistance: who should be concerned?. Curr Opin Infect Dis. 2020; 33(4):290-297. DOI: 10.1097/QCO.0000000000000662. View

2.
Melo A, Poester V, Trapaga M, Stevens D, Canabarro P, Adornes A . Aspergillosis in free-ranging Magellanic penguins. Med Mycol. 2023; 61(2). DOI: 10.1093/mmy/myad008. View

3.
Beernaert L, Pasmans F, Van Waeyenberghe L, Dorrestein G, Verstappen F, Vercammen F . Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother. 2009; 53(5):2199-201. PMC: 2681513. DOI: 10.1128/AAC.01492-08. View

4.
DIXON D, Wagner G, Shadomy S, Shadomy H . In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B. Chemotherapy. 1978; 24(6):364-7. DOI: 10.1159/000237809. View

5.
Wang D, Gricourt M, Arne P, Thierry S, Seguin D, Chermette R . Mutations in the Cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus isolated from avian farms in France and China. Poult Sci. 2014; 93(1):12-5. DOI: 10.3382/ps.2013-03541. View